Surgical Robot Firm Distalmotion Secures $150M for US Expansion
November 21, 2025, 9:34 am
Distalmotion receives $150M to boost US presence of DEXTER. The surgical robot system is set to expand in ambulatory surgery centers (ASCs). The focus is outpatient surgery. New funding fuels growth. A new chairman joins the board.
---
Distalmotion has secured $150 million. The funding will fuel the US expansion of its DEXTER surgical robot. This robotic system aims to simplify surgery. It targets ambulatory surgery centers (ASCs).
DEXTER is designed for flexibility. It is suited for outpatient settings. Its small size allows easy integration. It fits into any operating room. The robot can move between rooms. This maximizes efficiency.
The system supports smooth workflow. Surgeons can easily switch between methods. They can transition from laparoscopic to robotic techniques. Open architecture ensures compatibility. It works with current OR technologies. Cost-effective supply chains are supported.
Nearly 3,000 patients have been treated. This occurred across Europe and the US.
Ambulatory Surgery Centers (ASCs) are key. They represent a fast-growing sector. This growth is driven by outpatient procedures. ASCs prioritize efficiency.
DEXTER's features suit ASC needs. Its small footprint is ideal. It fits ASC operating rooms. Easy maneuverability is essential. Flexible workflows are crucial.
Chas McKhann is the new Executive Chairman. He brings 25 years of experience. His background is in MedTech and life sciences. McKhann led Apollo Endosurgery. He also led Silk Road Medical. He achieved significant sales growth.
Distalmotion aims to become a leader. The company wants to lead in ASC robotic surgery. McKhann's expertise is valuable.
Revival Healthcare Capital led the funding round. Existing investors also participated. This investment validates Distalmotion's vision. The company seeks to remove barriers to robotic surgery. Simplified operations are the key.
Distalmotion aims to empower access. They want access to the benefits of robotic surgery. DEXTER is central to this mission. The robot brings dexterity, precision, and ergonomics. It also offers flexibility and value.
DEXTER is a soft tissue robotic surgery system. It simplifies operations. It brings wristed robotics to any OR. The system's compact size is an advantage. It is mobile and easy to move.
* Improved surgical precision
* Enhanced ergonomics for surgeons
* Increased flexibility in surgical techniques
* Better workflow in operating rooms
* Greater efficiency in outpatient settings
The company is poised for growth. It will expand in the US and globally. DEXTER's adoption will accelerate. The focus remains on ASCs.
The funding supports product development. It also supports clinical initiatives.
---
Distalmotion has secured $150 million. The funding will fuel the US expansion of its DEXTER surgical robot. This robotic system aims to simplify surgery. It targets ambulatory surgery centers (ASCs).
DEXTER's Design
DEXTER is designed for flexibility. It is suited for outpatient settings. Its small size allows easy integration. It fits into any operating room. The robot can move between rooms. This maximizes efficiency.
The system supports smooth workflow. Surgeons can easily switch between methods. They can transition from laparoscopic to robotic techniques. Open architecture ensures compatibility. It works with current OR technologies. Cost-effective supply chains are supported.
Nearly 3,000 patients have been treated. This occurred across Europe and the US.
ASC Market Focus
Ambulatory Surgery Centers (ASCs) are key. They represent a fast-growing sector. This growth is driven by outpatient procedures. ASCs prioritize efficiency.
DEXTER's features suit ASC needs. Its small footprint is ideal. It fits ASC operating rooms. Easy maneuverability is essential. Flexible workflows are crucial.
Leadership Change
Chas McKhann is the new Executive Chairman. He brings 25 years of experience. His background is in MedTech and life sciences. McKhann led Apollo Endosurgery. He also led Silk Road Medical. He achieved significant sales growth.
Distalmotion aims to become a leader. The company wants to lead in ASC robotic surgery. McKhann's expertise is valuable.
Investor Confidence
Revival Healthcare Capital led the funding round. Existing investors also participated. This investment validates Distalmotion's vision. The company seeks to remove barriers to robotic surgery. Simplified operations are the key.
Distalmotion's Mission
Distalmotion aims to empower access. They want access to the benefits of robotic surgery. DEXTER is central to this mission. The robot brings dexterity, precision, and ergonomics. It also offers flexibility and value.
What is DEXTER?
DEXTER is a soft tissue robotic surgery system. It simplifies operations. It brings wristed robotics to any OR. The system's compact size is an advantage. It is mobile and easy to move.
Benefits of DEXTER
* Improved surgical precision
* Enhanced ergonomics for surgeons
* Increased flexibility in surgical techniques
* Better workflow in operating rooms
* Greater efficiency in outpatient settings
Distalmotion's Future
The company is poised for growth. It will expand in the US and globally. DEXTER's adoption will accelerate. The focus remains on ASCs.
The funding supports product development. It also supports clinical initiatives.